Prime Medicine, Inc.
Alpha-1 Anti-trypsin Deficiency (AATD)
Alpha-1 Anti-trypsin Deficiency
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for Alpha-1 Anti-trypsin Deficiency (AATD) in Alpha-1 Anti-trypsin Deficiency are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Prime Medicine expects to report initial clinical data from both WD and AATD programs in 2027.”